Former ResMed CFO Brett Sandercock joins 4DMedical Board

Melbourne, Australia, 16 November 2026: 4DMedical Limited ("ASX:4DX", "4DMedical" or the "Company"), a global leader in respiratory imaging technology, today announces the appointment of Brett Sandercock as independent Non-Executive Director, effective 16 November 2026.

Brett will chair the Audit and Risk Committee and join the Remuneration and Nomination Committee. Following his appointment, the Board's committees comprise:

- **Audit and Risk Committee:** Brett Sandercock (Chair), John Livingston, and Dr Robert Figlin
- **Remuneration and Nomination Committee:** John Livingston (Chair), Dr Geraldine McGinty, and Brett Sandercock
- **Medical Advisory Committee:** Dr Robert Figlin (Chair), Dr Geraldine McGinty, and Dr Christine Jenkins

Brett brings more than 30 years of finance leadership in global healthcare technology. He spent 27 years at ResMed (NYSE:RMD, ASX:RMD), including 20 years as Chief Financial Officer from 2006 until his retirement in May 2026. In that time, he helped lead ResMed through sustained growth and international expansion. His experience covers capital allocation, investor relations, mergers and acquisitions, risk management and building global finance teams. He continues to support ResMed as Special Advisor to the Chief Executive Officer.

Before becoming CFO, Brett held finance, treasury and audit roles at ResMed, the Saint-Gobain group, Healthcare of Australia and PwC. He holds a Bachelor of Economics from Macquarie University and is a member of Chartered Accountants Australia and New Zealand.

The Board considers Brett to be an independent director. Brett will stand for election at the Company's next Annual General Meeting.

4DMedical MD/CEO and Founder Andreas Fouras said:

Brett has lived the journey we are on. At ResMed he helped take an Australian respiratory technology company and build it into a global leader, through US market expansion, reimbursement, M&A and two decades of disciplined capital allocation. As we scale CT:VQ® across the US and Europe, and integrate our recent acquisitions, that experience is directly relevant to the decisions in front of us. Few executives combine his commercial judgement with such a deep understanding of healthcare technology, and I look forward to working closely with him.

4DMedical Executive Chair Julian Sutton said:

Brett's appointment adds significant financial, audit and governance experience to the Board, and he is exceptionally well qualified to Chair our Audit and Risk Committee. On behalf of the Board, I am delighted to welcome him to 4DMedical.

Brett Sandercock said:

I am excited to join the Board of 4DMedical at this important stage in the Company's growth. 4DMedical has compelling technology, a clear commercial opportunity and the potential to make a meaningful difference in respiratory care globally. I look forward to working with Andreas, my fellow directors and the broader team to support the Company's strategic priorities, strengthen its financial and governance capabilities, and help deliver sustainable long-term value for shareholders.

Melbourne
Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles
21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate
Investor Relations
investor.relations@4dmedical.com

Administration
Company Secretary
companysecretary@4dmedical.com

Media Enquiries
Julia Maguire
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ®** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its acquisition of **Imbio** in 2023 and **contextflow** in 2026, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

©4DMedical Limited